Big News From ESMO 2025 Changes Practice in Bladder Cancer
About this episode
The episode discusses significant findings from the ESMO 2025 that are set to change the standard of care for muscle-invasive bladder cancer.
Survival data from the KEYNOTE-905 trial and insights into the use of circulating tumor DNA to guide treatment decisions from IMvigor011 made big waves in bladder cancer care at the European Society of Medical Oncology Annual Congress. “Overall, this is going to change the standard of care for muscle-invasive bladder cancer,” says Amanda Nizam, MD, a genitourinary medical oncologist at the Cleveland Clinic Taussig Cancer Institute. She and Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, discuss how the findings are being incorporated into clinic and what questions remain. “I am continually surprised by the changes taking place in bladder cancer management,” notes Dr. Figlin. Dr. Nizam reported various financial relationships. Dr. Figlin reported various financial relationships.
More episodes of Oncology News Central Peer-Spectives
- New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
- Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
- Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
- Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
- “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
- “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC
Explore listener stats, chart rankings, contacts and more on the Oncology News Central Peer-Spectives podcast page.